Roche/Prothena

Pasinezumab is an antibody that binds to alpha-synuclein, so it will be broken down by the immune system. However, various clinical trials showed disappointing results. One reason is that such antibodies mainly work outside the cells, while alpha-synuclein mainly accumulates inside cells. Also, this approach does not address the root cause why alpha-synuclein accumulates in the first place.